Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 5.85%
As of Thursday, October 01, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 5.85%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Commentary & Analysis
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 6.46%
As of Wednesday, September 23, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 6.46%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Up 6.46%
As of Thursday, September 17, Eikon Therapeutics, Inc.’s EIKN share price has surged by 6.46%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 5.32%
As of Wednesday, September 16, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 5.32%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Eikon Therapeutics, Inc.’s (EIKN) Stock Is Down 6.80%
As of Thursday, September 10, Eikon Therapeutics, Inc.’s EIKN share price has dipped by 6.80%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $404.6 | $242.6 | 35% |
|
| Shares Out (Mil) | 54.1 | 54.0 | 49% |
|
| Institutional Ownership | 88.1% | 93.1% | 56% |
|
| Float (Mil) | 32.5 | 41.4 | 37% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 555 | 633 | 59% |
|
| Price Change (52-week) |
na | 50.0% | na |
|
| Growth | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | ($1.575) | ($6.412) | ($6.334) | |
| Month Ago EPS | ($1.575) | ($6.412) | ($6.334) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($1.556) | ($6.349) | ($6.185) | |
| Year/Year Chg | (3.6%) | (94.4%) | (94.5%) | |
| Financials | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($322) | ($44) | 4% |
|
| EPS (TTM) | ($13.722) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($256) | ($34) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($30) | $2 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $243 | $4 | 52% |
|
| Enterprise Value (Q1) (Mil) | $338 | $177 | 30% |
|
| Valuation | EIKN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.87 | 2.33 | 20% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | EIKN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (82.7%) | (47.6%) | 7% |
|
| ROE | 611.1% | (54.9%) | 100% |
|
| Liabilities to Assets | 40.2% | 29.3% | 31% |
|
| F-Score | 1 | 3 | na |
|
Eikon Therapeutics, Inc. did not pass any screens on 10/9/2026.
